New Diagnostic Test Follows Footsteps Leading to Esophageal Cancer
the Cancer Therapy Advisor take:
Frequent acid reflux, if left untreated, damages esaphageal cells and may lead to Barrett’s esophagus, a potential precursor of esophageal cancer. However, most patients with Barrett’s esophagus will not progress to esophageal cancer.
According to a study published in Nature Genetics, the discovery of a gene mutation that marks the pathway from a relatively harmless esophageal condition to cancer can lead to the development of a diagnostic test for patients with Barrett’s esophagus.
Study author Rebecca Fitzgerald and researchers mapped out the genetic similarities and differences between patients with Barrett’s esophagus and patients with esophageal cancer. Through this process, researchers discovered mutations in the gene TP53.
They developed a sponge-on-a-string test, also called the Cytosponge test, in which a patient swallows a capsule attached to a piece of thread. Once the capsule reaches the stomach, it dissolves to reveal a sponge underneath. Then a nurse uses the string to pull the sponge out to collect cells from the esophagus.
Fitzgerald said she hopes the Cytosponge test will be routinely available in hospitals in the near future. This will allow patients to be diagnosed at early stages of the disease, where treatment has a greater chance of being effective. Currently, even Barrett’s esophagus is widely undiagnosed.

New Diagnostic Test Follows Footsteps Leading to Esophageal Cancer
A new diagnostic test may be around the corner thanks to the discovery of a gene mutation that marks the progression from a harmless esophageal condition to cancer, according to research published in Nature Genetics. Over time, frequent acid reflux—often called heartburn—damages the cells in the esophagus.
Scientists funded by Cancer Research UK's Catalyst Club, and working as part of the International Cancer Genome Consortium (ICGC), have identified the faults that signal the early onset of esophageal cancer.
Related Resources
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Prostate Cancer | Regimens | Drugs |
Rare Cancers | Regimens | |
Renal Cell Carcinoma | Regimens | Drugs |
Skin Cancer | Regimens | Drugs |
Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed